On the evening of December 22, Fosun Pharmaceutical issued an announcement to respond to the Shanghai Stock Exchange's letter on the supervision of Lvgu Pharmaceutical's investment matters. The 27-page PDF announcement document detailed 971's past sales data, subsequent clinical developments, and various market concerns. The latest response letter revealed sales data for 971. Specifically, from approval in 2019 to September 2025, the total sales amount of 971 reached 1.92 billion yuan, with sales volume of 6.7711 million boxes, of which 102 million yuan was sold for the first nine months of 2025, and the sales volume was 468,800 yuan. According to Fosun Pharmaceutical, the above test plan design has been approved by the Drug Evaluation Center of the State Drug Administration. As of December 15, 2025, a total of 580 cases have been enrolled in this clinical study. Based on the estimates of this clinical research plan, all subjects will be able to complete enrollment by the end of 2027, complete relevant research and read data in early 2029, and submit clinical trial summary reports and other data to the State Drug Administration in the first half of 2029.

On the evening of December 22, Fosun Pharmaceutical issued an announcement to respond to the Shanghai Stock Exchange's letter on the supervision of Lvgu Pharmaceutical's investment matters. The 27-page PDF announcement document detailed 971's past sales data, subsequent clinical developments, and various market concerns. The latest response letter revealed sales data for 971. Specifically, from approval in 2019 to September 2025, the total sales amount of 971 reached 1.92 billion yuan, with sales volume of 6.7711 million boxes, of which 102 million yuan was sold for the first nine months of 2025, and the sales volume was 468,800 yuan. According to Fosun Pharmaceutical, the above test plan design has been approved by the Drug Evaluation Center of the State Drug Administration. As of December 15, 2025, a total of 580 cases have been enrolled in this clinical study. Based on the estimates of this clinical research plan, all subjects will be able to complete enrollment by the end of 2027, complete relevant research and read data in early 2029, and submit clinical trial summary reports and other data to the State Drug Administration in the first half of 2029.